Literature DB >> 16569889

Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients.

Jennifer L Reedy1, Shahid Husain, Michael Ison, Timothy L Pruett, Nina Singh, Joseph Heitman.   

Abstract

In Candida albicans, calcineurin mediates tolerance to azole antifungal drugs, survival in serum, and virulence. In this study, we examined 24 Candida isolates from liver transplant recipients receiving a calcineurin inhibitor as a component of their immunosuppressive therapy. We were unable to detect a difference in susceptibility to calcineurin inhibitors in combination with fluconazole, serum, or calcium in these isolates.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569889      PMCID： PMC1426937          DOI： 10.1128/AAC.50.4.1573-1577.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Fungal infections in the recipients of solid organ transplantation.

Authors:  Nina Singh
Journal:  Infect Dis Clin North Am       Date:  2003-03       Impact factor: 5.982

2.  Calcineurin is required for Candida albicans to survive calcium stress in serum.

Authors:  Jill R Blankenship; Joseph Heitman
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Calcineurin is essential for survival during membrane stress in Candida albicans.

Authors:  M Cristina Cruz; Alan L Goldstein; Jill R Blankenship; Maurizio Del Poeta; Dana Davis; Maria E Cardenas; John R Perfect; John H McCusker; Joseph Heitman
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

4.  Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans.

Authors:  M C Cruz; D S Fox; J Heitman
Journal:  EMBO J       Date:  2001-03-01       Impact factor: 11.598

5.  Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices.

Authors:  Nina Singh; Marilyn M Wagener; Ignazio R Marino; Timothy Gayowski
Journal:  Transplantation       Date:  2002-01-15       Impact factor: 4.939

6.  Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.

Authors:  O Marchetti; J M Entenza; D Sanglard; J Bille; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Calcineurin is essential for virulence in Candida albicans.

Authors:  Teresa Bader; Barbara Bodendorfer; Klaus Schröppel; Joachim Morschhäuser
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence.

Authors:  Dominique Sanglard; Françoise Ischer; Oscar Marchetti; José Entenza; Jacques Bille
Journal:  Mol Microbiol       Date:  2003-05       Impact factor: 3.501

9.  Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study.

Authors:  Shahid Husain; Jan Tollemar; Edward A Dominguez; Katherine Baumgarten; Atul Humar; David L Paterson; Marilyn M Wagener; Shimon Kusne; Nina Singh
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

10.  Calcineurin is essential for Candida albicans survival in serum and virulence.

Authors:  Jill R Blankenship; Floyd L Wormley; Molly K Boyce; Wiley A Schell; Scott G Filler; John R Perfect; Joseph Heitman
Journal:  Eukaryot Cell       Date:  2003-06
View more
  8 in total

Review 1.  Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Authors:  Sharon C-A Chen; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

Review 2.  Antifungal adjuvants: Preserving and extending the antifungal arsenal.

Authors:  Arielle Butts; Glen E Palmer; P David Rogers
Journal:  Virulence       Date:  2016-07-26       Impact factor: 5.882

Review 3.  Signaling cascades as drug targets in model and pathogenic fungi.

Authors:  Robert J Bastidas; Jennifer L Reedy; Helena Morales-Johansson; Joseph Heitman; Maria E Cardenas
Journal:  Curr Opin Investig Drugs       Date:  2008-08

4.  Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms.

Authors:  Priya Uppuluri; Jeniel Nett; Joseph Heitman; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

5.  High-throughput nano-biofilm microarray for antifungal drug discovery.

Authors:  Anand Srinivasan; Kai P Leung; Jose L Lopez-Ribot; Anand K Ramasubramanian
Journal:  MBio       Date:  2013-06-25       Impact factor: 7.867

6.  Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations.

Authors:  Jessica A Hill; Ron Ammar; Dax Torti; Corey Nislow; Leah E Cowen
Journal:  PLoS Genet       Date:  2013-04-04       Impact factor: 5.917

7.  Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay.

Authors:  Ikechukwu Okoli; Jeffrey J Coleman; Emmanouil Tampakakis; Emmanouil Tempakakis; W Frank An; Edward Holson; Florence Wagner; Annie L Conery; Jonah Larkins-Ford; Gang Wu; Andy Stern; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

8.  The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms.

Authors:  Wei Jia; Haiyun Zhang; Caiyun Li; Gang Li; Xiaoming Liu; Jun Wei
Journal:  BMC Microbiol       Date:  2016-06-18       Impact factor: 3.605
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.